CA2514152A1 - Use of bradykinin-b2 receptor antagonists for treating osteoarthrosis - Google Patents
Use of bradykinin-b2 receptor antagonists for treating osteoarthrosis Download PDFInfo
- Publication number
- CA2514152A1 CA2514152A1 CA002514152A CA2514152A CA2514152A1 CA 2514152 A1 CA2514152 A1 CA 2514152A1 CA 002514152 A CA002514152 A CA 002514152A CA 2514152 A CA2514152 A CA 2514152A CA 2514152 A1 CA2514152 A1 CA 2514152A1
- Authority
- CA
- Canada
- Prior art keywords
- arg
- pro
- tic
- oic
- gly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/043—Kallidins; Bradykinins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Peptides that have a Bradykinin-antagonistic effect are suitable for the production of drugs for use in the prophylaxis and therapy of diseases whose progression is associated with an increased activity of matrix metalloproteinases. These diseases include degenerative articular diseases, for example osteoarthrosis, spondylosis and chondroporosis after joint trauma or prolonged joint immobilization after meniscus or patella injuries or ruptures of a ligament.
Claims (3)
1. The use of the compound of the formula I
A-B-X-E-F-K-(D)-TIC-GM-M-F'-I (I) selected from the group:
H-(D)-Arg-Arg-Pro-Hyp-Gly-Thia-Ser-(D)-Tic-Oic-Arg-OH, H-(D)-Arg-Arg-Pro-Pro-Gly-Thia-Ser-(D)-Tic-Oic-Arg-OH, H-(D)-Arg-Arg-Pro-Hyp-Gly-Phe-Ser-(D)-Tic-Oic-Arg-OH, H-(D)-Arg-Arg-Hyp-Pro-Gly-Phe-Ser-(D)-Tic-Oic-Arg-OH and H-(D)-Arg-Arg-Pro-Pro-Gly-Phe-Ser-(D)-Tic-Oic-Arg-OH
for the production of pharmaceuticals for the prophylaxis and therapy of osteoarthrosis, spondylosis, chondroporosis after joint trauma or relatively long immobilization of a joint after meniscus or patella injuries or torn ligaments.
A-B-X-E-F-K-(D)-TIC-GM-M-F'-I (I) selected from the group:
H-(D)-Arg-Arg-Pro-Hyp-Gly-Thia-Ser-(D)-Tic-Oic-Arg-OH, H-(D)-Arg-Arg-Pro-Pro-Gly-Thia-Ser-(D)-Tic-Oic-Arg-OH, H-(D)-Arg-Arg-Pro-Hyp-Gly-Phe-Ser-(D)-Tic-Oic-Arg-OH, H-(D)-Arg-Arg-Hyp-Pro-Gly-Phe-Ser-(D)-Tic-Oic-Arg-OH and H-(D)-Arg-Arg-Pro-Pro-Gly-Phe-Ser-(D)-Tic-Oic-Arg-OH
for the production of pharmaceuticals for the prophylaxis and therapy of osteoarthrosis, spondylosis, chondroporosis after joint trauma or relatively long immobilization of a joint after meniscus or patella injuries or torn ligaments.
2. The use as claimed in claim 1, wherein the compound D-arginyl-L-arginyl-L-prolyl-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-(3R)-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-(2S,3aS,7aS)-octahydro-1H-indole-2-carbonyl-L-arginine is employed.
3. The use of the compound of the formula I as claimed in claims 1 or 2, wherein the administration is carried out by subcutaneous, intraarticular, intraperitoneal or intravenous injection or transdermal administration.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10304994.0 | 2003-02-07 | ||
| DE10304994A DE10304994A1 (en) | 2003-02-07 | 2003-02-07 | The use of antagonists of the bradykinin B2 receptor for the treatment of osteoarthrosis |
| PCT/EP2004/000550 WO2004069266A2 (en) | 2003-02-07 | 2004-01-23 | Use of bradykinin-b2 receptor antagonists for treating osteoarthrosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2514152A1 true CA2514152A1 (en) | 2004-08-19 |
| CA2514152C CA2514152C (en) | 2012-01-17 |
Family
ID=32797325
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2514152A Expired - Fee Related CA2514152C (en) | 2003-02-07 | 2004-01-23 | Use of bradykinin-b2 receptor antagonists for treating osteoarthrosis |
Country Status (31)
| Country | Link |
|---|---|
| EP (1) | EP1594520B1 (en) |
| JP (1) | JP2006516980A (en) |
| KR (1) | KR20050105447A (en) |
| CN (1) | CN1317029C (en) |
| AR (1) | AR043036A1 (en) |
| AT (1) | ATE335500T1 (en) |
| AU (1) | AU2004210396A1 (en) |
| BR (1) | BRPI0407333A (en) |
| CA (1) | CA2514152C (en) |
| CO (1) | CO5690613A2 (en) |
| CY (1) | CY1105708T1 (en) |
| DE (2) | DE10304994A1 (en) |
| DK (1) | DK1594520T3 (en) |
| ES (1) | ES2268622T3 (en) |
| HK (1) | HK1085926A1 (en) |
| HR (1) | HRP20050701B1 (en) |
| IL (1) | IL169899A0 (en) |
| MA (1) | MA27618A1 (en) |
| ME (1) | MEP41008A (en) |
| MX (1) | MXPA05007310A (en) |
| MY (1) | MY135827A (en) |
| NO (1) | NO333903B1 (en) |
| NZ (1) | NZ541680A (en) |
| PE (1) | PE20040939A1 (en) |
| PL (1) | PL206412B1 (en) |
| PT (1) | PT1594520E (en) |
| RS (1) | RS51029B (en) |
| RU (1) | RU2329057C2 (en) |
| TW (1) | TW200505472A (en) |
| WO (1) | WO2004069266A2 (en) |
| ZA (1) | ZA200505177B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0710522D0 (en) * | 2007-06-01 | 2007-07-11 | Royal Veterinary College The | Drug delivery system comprising matrix metalloproteinase inhibitors |
| IT1391236B1 (en) | 2008-07-11 | 2011-12-01 | St Luso Farm D'italia Spa | PHARMACEUTICAL COMPOSITIONS BASED ON ANTAGONISTS OF THE B2 KININE AND CORTICOSTEROID RECEPTOR AND THEIR USE |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE63490B1 (en) * | 1988-11-24 | 1995-05-03 | Hoechst Ag | Peptides having bradykinin antagonist action |
| MX9100717A (en) * | 1990-08-24 | 1992-04-01 | Syntex Inc | BRADIQUININE ANTAGONISTS |
| FR2751650B1 (en) * | 1996-07-24 | 1998-10-09 | Fournier Ind & Sante | NOVEL N-BENZENESULFONYL-L-PROLINE COMPOUNDS, METHOD OF PREPARATION AND THERAPEUTIC USE |
| CA2364178C (en) * | 2000-12-05 | 2006-01-10 | Yasuhiro Katsu | N-benzenesulfonyl l-proline compounds as bradykinin antagonists |
| JP2005519917A (en) * | 2002-02-01 | 2005-07-07 | オメロス コーポレイション | Compositions and methods for systemic inhibition of cartilage degradation |
-
2003
- 2003-02-07 DE DE10304994A patent/DE10304994A1/en not_active Withdrawn
-
2004
- 2004-01-13 PE PE2004000064A patent/PE20040939A1/en not_active Application Discontinuation
- 2004-01-23 AT AT04704552T patent/ATE335500T1/en active
- 2004-01-23 NZ NZ541680A patent/NZ541680A/en not_active IP Right Cessation
- 2004-01-23 CN CNB2004800034498A patent/CN1317029C/en not_active Expired - Fee Related
- 2004-01-23 WO PCT/EP2004/000550 patent/WO2004069266A2/en active IP Right Grant
- 2004-01-23 AU AU2004210396A patent/AU2004210396A1/en not_active Abandoned
- 2004-01-23 JP JP2006501585A patent/JP2006516980A/en active Pending
- 2004-01-23 CA CA2514152A patent/CA2514152C/en not_active Expired - Fee Related
- 2004-01-23 DE DE502004001159T patent/DE502004001159D1/en not_active Expired - Lifetime
- 2004-01-23 PT PT04704552T patent/PT1594520E/en unknown
- 2004-01-23 PL PL376605A patent/PL206412B1/en unknown
- 2004-01-23 ES ES04704552T patent/ES2268622T3/en not_active Expired - Lifetime
- 2004-01-23 ME MEP-410/08A patent/MEP41008A/en unknown
- 2004-01-23 BR BR0407333-9A patent/BRPI0407333A/en not_active IP Right Cessation
- 2004-01-23 RU RU2005127862/15A patent/RU2329057C2/en not_active IP Right Cessation
- 2004-01-23 DK DK04704552T patent/DK1594520T3/en active
- 2004-01-23 RS YUP-2005/0565A patent/RS51029B/en unknown
- 2004-01-23 KR KR1020057014116A patent/KR20050105447A/en not_active Application Discontinuation
- 2004-01-23 EP EP04704552A patent/EP1594520B1/en not_active Expired - Lifetime
- 2004-01-23 MX MXPA05007310A patent/MXPA05007310A/en active IP Right Grant
- 2004-02-05 AR ARP040100363A patent/AR043036A1/en unknown
- 2004-02-05 TW TW093102562A patent/TW200505472A/en unknown
- 2004-02-06 MY MYPI20040362A patent/MY135827A/en unknown
-
2005
- 2005-06-27 ZA ZA200505177A patent/ZA200505177B/en unknown
- 2005-07-26 IL IL169899A patent/IL169899A0/en unknown
- 2005-08-03 CO CO05076615A patent/CO5690613A2/en not_active Application Discontinuation
- 2005-08-04 HR HRP20050701AA patent/HRP20050701B1/en not_active IP Right Cessation
- 2005-08-05 MA MA28425A patent/MA27618A1/en unknown
- 2005-09-06 NO NO20054144A patent/NO333903B1/en not_active IP Right Cessation
-
2006
- 2006-05-25 HK HK06106009A patent/HK1085926A1/en not_active IP Right Cessation
- 2006-10-16 CY CY20061101482T patent/CY1105708T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AP1818A (en) | Urea-compounds active as vanilloid receptor antagonists for the treatment of pain | |
| BRPI0413232B8 (en) | compound having inhibitory activity against sodium-dependent carrier, pharmaceutical composition comprising the compound, use of the compound in the preparation of a medicine, and process for preparing the compound | |
| BRPI0409136A (en) | pentacyclic heteroaromatic compound and medicinal use thereof | |
| ID21696A (en) | ANTRANILATE ACID DERIVATION AS MULTI MEDICINE RESISTANCE MODULATOR | |
| BR0209249A (en) | Heterocyclic Compound Derivatives and Medicines | |
| AR035828A1 (en) | CHANNEL OPENER K ACTIVATED BY CALCIUM OF GREAT CONDUCTANCE, USE OF THE SAME OR A SUBSTITUTED AZOL COMPOUND TO PREPARE A MEDICINAL PRODUCT, SUBSTITUTED AZOL COMPOUND, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE TO PREPARE A MEDICINAL PRODUCT | |
| IN2015DN01132A (en) | ||
| BR0308996A (en) | Quinolinone derivatives | |
| WO2003061768A3 (en) | Use of a compound inactivating the kinase a protein in a composition containing a cosmetically acceptable medium in order to lighten the skin | |
| AU7453498A (en) | Sulfonamide derivatives, their production and use | |
| MX2007008614A (en) | Peptides with neuropeptide-2 receptor (y2r) agonist activity. | |
| WO2005056524A3 (en) | Therapeutic agents useful for treating pain | |
| WO2003006016A3 (en) | Use of nk-1 receptor antagonists with pyridinic structure, for the treatment of brain, spinal or nerve injury | |
| CL2004001050A1 (en) | 3 'DERIVED COMPOUND - [4-OXO-3 - {[(CICLOPROPIL OR 2,2,2-TRIFLUOROETIL) AMINO] CARBONIL} -1,8-NAFTIRIDIN-1 (4H) -IL] -3-REPLACED-1 -1'-BIFENIL-4-IL; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OR PREVENTION OF ASTHMA, CHRONIC BRONCHITIS, PUL DISEASE | |
| CA2157792A1 (en) | N-(3-piperidinyl-carbonyl)-beta-alanine derivatives as paf antagonists | |
| CA2514152A1 (en) | Use of bradykinin-b2 receptor antagonists for treating osteoarthrosis | |
| US20070088073A1 (en) | Method for treating pain | |
| WO2004026837A3 (en) | Histamine h3 receptor antagonists, preparaton and therapeutic uses | |
| WO2004078744A3 (en) | Urea derivatives and their use as vanilloid receptor antagonists in the treatment of pain | |
| MXPA05013233A (en) | Heteroaryl-substituted imdazole derivatives as glutamate receptor antagonists. | |
| MY139613A (en) | Novel piperazinyl-pyrazinone derivatives for the treatment of 5-ht2a receptor-related disorders | |
| Hawkes | N-BENZYL-β-CHLOROPROPIONAMIDE (HIBICON®): A New Approach to Anticonvulsant Therapy | |
| WO2003068166A3 (en) | Treatment of ophthalmic disorders using urea and urea derivatives | |
| NO20013480D0 (en) | Drug for dry skin | |
| CA2392902A1 (en) | Substituted bisindolylmaleimides for the inhibition of cell proliferation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20160125 |